{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:07Z","timestamp":1792511527985,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.autrev.2023.103468","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:19:17Z","timestamp":1698149957000},"page":"103468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues"],"prefix":"10.1016","volume":"22","author":[{"given":"Thomas","family":"Khoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103468_bb0005","first-page":"1","article-title":"Changes in the leading cause of death: recent patterns in heart disease and cancer mortality","author":"Heron","year":"2016","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.autrev.2023.103468_bb0010","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103468_bb0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2023.103468_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2023.103468_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.18773\/austprescr.2020.075","article-title":"Top 10 drugs 2019-20","volume":"43","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.autrev.2023.103468_bb0030","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1111\/bcp.13709","article-title":"The \u2019top 100\u2032 drugs and classes in England: an updated \u2018starter formulary\u2019 for trainee prescribers","volume":"84","author":"Audi","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2023.103468_bb0035","first-page":"6","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice","author":"Fuentes","year":"2018","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.autrev.2023.103468_bb0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"C. Cholesterol Treatment Trialists","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103468_bb0045","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2023.103468_bb0050","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.autrev.2013.07.001","article-title":"Statin-induced necrotizing myositis - a discrete autoimmune entity within the \u201cstatin-induced myopathy spectrum\u201d","volume":"12","author":"Hamann","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103468_bb0055","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/08971900211040291","article-title":"Statin-associated autoimmune myopathy: review of the literature","volume":"36","author":"Barrons","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.autrev.2023.103468_bb0065","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-induced anti-HMGCR-associated myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2023.103468_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR Myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2023.103468_bb0075","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103468_bb0080","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103468_bb0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103468_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2023.103468_bb0095","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory Myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of Anti-3-Hydroxy-3-Methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2023.103468_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866701","article-title":"Screening for anti-HMGCR antibodies in a large single myositis center reveals infrequent exposure to statins and diversiform presentation of the Disease","volume":"13","author":"Szczesny","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103468_bb0110","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103468_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000416","article-title":"Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: an observational study in Japan","volume":"94","author":"Watanabe","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103468_bb0120","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103468_bb0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009742.2019.1672782","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme a reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"49","author":"Aggarwal","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103468_bb0135","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.24993","article-title":"Long-term outcomes and prognosis factors in patients with idiopathic inflammatory Myopathies based on myositis-specific autoantibodies: a single cohort study","volume":"75","author":"Jiang","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2023.103468_bb0140","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/imj.13023","article-title":"HMGCR-associated myositis: a New Zealand case series and estimate of incidence","volume":"46","author":"Kennedy","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2023.103468_bb0145","first-page":"75","article-title":"Anti-HMGCR Immune-mediated Necrotising myopathy: calculation of incidence and confirmation of low malignancy risk in two independent cohorts. A retrospective case review [abstract]","author":"Khoo","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103468_bb0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.55563\/clinexprheumatol\/5y19bb","article-title":"Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies: incidence using different testing criteria, and case series","volume":"40","author":"Joseph","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0155","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/kev229","article-title":"Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience","volume":"54","author":"Klein","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103468_bb0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/mus.27504","article-title":"Incidence and prevalence of immune-mediated necrotizing myopathy in adults in Olmsted County","volume":"65","author":"Shelly","year":"2022","journal-title":"Minnesota Muscle Nerve"},{"key":"10.1016\/j.autrev.2023.103468_bb0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National Trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.autrev.2023.103468_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of Anti-3-Hydroxy-3-Methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory Myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103468_bb0175","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-021-05063-3","article-title":"The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme a reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry","volume":"42","author":"Gupta","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103468_bb0180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/kjm2.12240","article-title":"Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase myopathy","volume":"36","author":"Liang","year":"2020","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.autrev.2023.103468_bb0185","first-page":"26","article-title":"Immune-mediated necrotizing myopathy in a multi-ethnic Malaysian cohort","author":"Tan","year":"2021","journal-title":"Neurology Asia"},{"key":"10.1016\/j.autrev.2023.103468_bb0190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3988\/jcn.2022.0374","article-title":"Clinical and radiological features of Korean patients with anti-HMGCR myopathy","volume":"19","author":"Oh","year":"2023","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.autrev.2023.103468_bb0195","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.autrev.2023.103468_bb0200","first-page":"15","article-title":"Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy","author":"Adler","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2023.103468_bb0205","series-title":"Did shiitake mushrooms induce Immune- Mediated Necrotizing myopathy?","author":"Yoshida","year":"2019"},{"key":"10.1016\/j.autrev.2023.103468_bb0210","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00217-020-03435-w","article-title":"Fruiting bodies of selected edible mushrooms as a potential source of lovastatin","volume":"246","author":"Ka\u0142a","year":"2020","journal-title":"Eur Food Res Technol"},{"key":"10.1016\/j.autrev.2023.103468_bb0215","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1615\/IntJMedMushrooms.2017024413","article-title":"Water-soluble polysaccharide extracts from the oyster culinary-medicinal mushroom Pleurotus ostreatus (Agaricomycetes) with HMGCR inhibitory activity","volume":"19","author":"Gil-Ramirez","year":"2017","journal-title":"Int J Med Mushrooms"},{"key":"10.1016\/j.autrev.2023.103468_bb0220","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-145-6-200609190-00021","article-title":"Symptomatic myopathy due to red yeast rice","volume":"145","author":"Mueller","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0225","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/00007890-200210270-00028","article-title":"Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient","volume":"74","author":"Prasad","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2023.103468_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijfoodmicro.2013.03.018","article-title":"Exposure assessment of lovastatin in Pu-erh tea","volume":"164","author":"Zhao","year":"2013","journal-title":"Int J Food Microbiol"},{"key":"10.1016\/j.autrev.2023.103468_bb0235","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/mus.27758","article-title":"Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa","volume":"67","author":"Yaworski","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2023.103468_bb0240","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1995-7645(12)60180-1","article-title":"Antihypercholesterolemic effect of Bacopa monniera Linn. On high cholesterol diet induced hypercholesterolemia in rats","volume":"5","author":"Kamesh","year":"2012","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0245","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/imj.13816","article-title":"Over-representation of statin-associated necrotising myopathy in patients of aboriginal and Torres Strait islander heritage","volume":"48","author":"Day","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2023.103468_bb0250","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nmd.2020.02.003","article-title":"Clinical and histological features of immune-mediated necrotising myopathy: a multi-Centre south Australian cohort study","volume":"30","author":"Day","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2023.103468_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/imj.13575","article-title":"Statin-associated immune-mediated necrotising myopathy: a New Zealand case series showing possible overrepresentation in Pacific islanders","volume":"48","author":"Woolley","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2023.103468_bb0260","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/keaa337","article-title":"Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies","volume":"60","author":"Close","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103468_bb0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1034\/j.1399-0039.2002.590506.x","article-title":"HLA-DRB1 and HLA-DQB1 polymorphisms in Pacific Islands populations","volume":"59","author":"Velickovic","year":"2002","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.autrev.2023.103468_bb0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2023.103468_bb0275","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2023.103468_bb0280","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.27382","article-title":"Statin-associated anti-3-hydroxy-3-methyl-glutaryl-coenzyme a reductase (HMGCR) myopathy: imaging findings on thigh-muscle magnetic resonance imaging (MRI) in six patients","volume":"64","author":"Lee","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2023.103468_bb0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jocn.2018.08.010","article-title":"Statin-naive anti-HMGCR antibody-mediated necrotizing myopathy in China","volume":"57","author":"Jiao","year":"2018","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2023.103468_bb0290","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005694","article-title":"Atorvastatin-induced necrotizing autoimmune myositis: an emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype","volume":"96","author":"Troyanov","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103468_bb0295","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/BOR.0000000000000753","article-title":"Cardiac involvement in inflammatory myopathies and inherited muscle diseases","volume":"32","author":"Lilleker","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0300","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s10067-019-04678-z","article-title":"Cardiac involvement in idiopathic inflammatory myopathies detected by cardiac magnetic resonance imaging","volume":"38","author":"Khoo","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0305","doi-asserted-by":"crossref","first-page":"1094611","DOI":"10.3389\/fimmu.2023.1094611","article-title":"Characteristics of cardiac involvement in immune-mediated necrotizing myopathy","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103468_bb0310","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.mayocp.2020.03.032","article-title":"Cardiac and respiratory complications of Necrotizing autoimmune myopathy","volume":"95","author":"Triplett","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2023.103468_bb0315","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jeab140","article-title":"Anti-HMGCR myopathy with cardiac involvement","author":"Wegner","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.autrev.2023.103468_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.571716","article-title":"Case report: Immune Mediated Necrotizing myopathy with IgG antibodies to 3-Hydroxy-3-Methylglutaryl-coenzyme a reductase (HMGCR) may present with acute systolic heart failure","volume":"11","author":"Ghannam","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2023.103468_bb0325","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/cns.13658","article-title":"Juvenile idiopathic inflammatory myopathies with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies in a Chinese cohort","volume":"27","author":"Hou","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2023.103468_bb0330","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2023.103468_bb0335","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2022.04.017","article-title":"Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: single-center experience and literature review","volume":"101","author":"Prieto-Pena","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0340","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0037-1604402","article-title":"Anti-HMGCR antibody-related Necrotizing autoimmune myopathy mimicking muscular dystrophy","volume":"48","author":"Tard","year":"2017","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.autrev.2023.103468_bb0345","first-page":"105","article-title":"Anti-HMGCR antibodies and asymptomatic hyperCKemia. A case report","volume":"40","author":"Torri","year":"2021","journal-title":"Acta Myol"},{"key":"10.1016\/j.autrev.2023.103468_bb0350","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/pn-2022-003589","article-title":"Anti-HMGCR myopathy: barriers to prompt recognition","volume":"23","author":"Barp","year":"2023","journal-title":"Pract Neurol"},{"key":"10.1016\/j.autrev.2023.103468_bb0355","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000523","article-title":"Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy","volume":"6","author":"Mohassel","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2023.103468_bb0360","article-title":"Chronic onset form of anti-HMG-CoA reductase myopathy","volume":"8","author":"Lorenzo-Villalba","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105871","article-title":"Anti-HMGCR myopathy mimicking limb-girdle muscular dystrophy and the response to rituximab","volume":"194","author":"Idiculla","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.autrev.2023.103468_bb0370","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217831120","article-title":"Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone","volume":"120","author":"Yogev","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2023.103468_bb0375","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ajhg.2023.04.006","article-title":"Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophy","volume":"110","author":"Morales-Rosado","year":"2023","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.autrev.2023.103468_bb0380","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103468_bb0385","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2023.103468_bb0390","article-title":"Statin induced myopathy among patients attending the National Center for diabetes, endocrinology, & genetics","volume":"74","author":"Abed","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.autrev.2023.103468_bb0395","doi-asserted-by":"crossref","first-page":"320","DOI":"10.55563\/clinexprheumatol\/2ao5ze","article-title":"Treatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-Centre cohort and published data","volume":"40","author":"Rademacher","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0400","doi-asserted-by":"crossref","DOI":"10.1111\/imj.16004","article-title":"Clinical associations of patients with anti-3-hydroxy-3-methylglutaryl CoA reductase antibody-associated immune-mediated necrotising myopathy","author":"Tan","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2023.103468_bb0405","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2016.09.005","article-title":"Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories","volume":"15","author":"Alvarado-Cardenas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103468_bb0410","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","article-title":"The risk of muscular events among New users of hydrophilic and lipophilic statins: an observational cohort study","volume":"36","author":"Mueller","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0415","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.2337\/dc17-S012","volume":"40","author":"9. Cardiovascular Disease and Risk Management","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2023.103468_bb0420","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/DHPS.S333738","article-title":"A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management","volume":"13","author":"Safitri","year":"2021","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.autrev.2023.103468_bb0425","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"S.C. Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0430","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.12.121","article-title":"Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins","volume":"12","author":"Morikawa","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.autrev.2023.103468_bb0435","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2023.103468_bb0440","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10067-017-3831-2","article-title":"Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-Centre cohort","volume":"37","author":"Waters","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0445","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103468_bb0450","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103468_bb0455","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2023.103468_bb0460","first-page":"74","article-title":"Cancer screening recommendations for patients with idiopathic inflammatory myopathy [abstract]","author":"Oldroyd","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0465","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00296-017-3821-3","article-title":"Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review","volume":"38","author":"Borges","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103468_bb0470","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jamainternmed.2018.2859","article-title":"Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population","volume":"178","author":"Caughey","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0475","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0480","first-page":"10","article-title":"Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model","author":"Julien","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2023.103468_bb0485","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1093\/rheumatology\/keac198","article-title":"Statin-associated immune-mediated necrotizing myositis in native Americans","volume":"61","author":"Muruganandam","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103468_bb0490","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2023.103468_bb0495","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103468_bb0500","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.nmd.2016.08.013","article-title":"Treatment and outcomes in necrotising autoimmune myopathy: an Australian perspective","volume":"26","author":"Ashton","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2023.103468_bb0505","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of Disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2023.103468_bb0510","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2023.103468_bb0515","first-page":"666","article-title":"Management strategies for statin-associated muscle symptoms: how useful is same-statin rechallenge?","volume":"33","author":"Brennan","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2023.103468_bb0520","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-020-00942-3","article-title":"Lipid-lowering therapies in myositis","volume":"22","author":"Mizus","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2023.103468_bb0525","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.40919","article-title":"Use of proprotein convertase Subtilisin\/Kexin type 9 inhibitors in statin-associated Immune-Mediated Necrotizing myopathy: a case series","volume":"71","author":"Tiniakou","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103468_bb0530","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103468_bb0535","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103468_bb0540","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2522\/ptj.20090251","article-title":"Effects of statins on skeletal muscle: a perspective for physical therapists","volume":"90","author":"Di Stasi","year":"2010","journal-title":"Phys Ther"},{"key":"10.1016\/j.autrev.2023.103468_bb0545","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.21103","article-title":"Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction","volume":"52","author":"Nagaraju","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:31:21Z","timestamp":1761600681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":109,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1568997223002021"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103468","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103468"}}